Ranbaxy Sees "Progress" On Discussions With U.S. FDA, DOJ; Keeps Lipitor Launch Hopes Alive
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After staying non-committal for several months, Daiichi-Sankyo controlled Ranbaxy Laboratories Ltd. now says it has engaged in wide-ranging negotiations with U.S. FDA and the Department of Justice on multiple issues related to the alleged violation of good manufacturing practices at two of its India-based sites in Paonta Sahib and Dewas